RxDoctor Payments Data

Zaher Al Shallah, MD

Nephrology · Germantown, TNNPI 1356399117

Payments from drug & device makers

$2,292in general payments, 2019–2025

Across 102 payments — averaging $22.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Travere Therapeutics, Inc.$501
  • AstraZeneca$324
  • Bayer$249
  • Fresenius USA Marketing, Inc.$181
  • Ardelyx, Inc.$175
  • Vifor Pharma, Inc.$171
  • plus $690 from 11 others

What the payments were for

  • Food & beverage$2,18395%
  • Education$1095%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,292 in reported general payments places this provider in the 60th percentile of 229 nephrology providers in Tennessee.

See all nephrology providers in Tennessee

Medicare billing

Part B allowed, 2024
$251,830
Medicare patients
481
Services billed
2,236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide79$162,570
XphozahTenapanor Hcl27$88,298
JardianceEmpagliflozin11$11,215
Sevelamer Carbonate67$10,595
FarxigaDapagliflozin Propanediol13$9,493
EliquisApixaban11$6,863
Clonidine26$4,008
SpsSodium Polystyrene Sulfon/Sorb16$3,375
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp11$2,892
Nifedipine ErNifedipine85$1,913
Bumetanide39$1,454
Calcium Acetate14$1,400
Midodrine Hcl11$843
Atorvastatin Calcium68$791
Tamsulosin Hcl44$782

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$181$162,57079 claims
Boehringer IngelheimJardiance$20$11,21511 claims
AstraZenecaFarxiga$324$9,49313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 229 nephrology providers in Tennessee.

Other nephrology in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →